Medtronic

Loading

Overview

The Medtronic Newsroom is designed to assist media in finding news and information about our company.

Medtronic, founded in a Minneapolis garage in 1949 by Earl Bakken and his brother-in-law, Palmer Hermundslie, is the world’s leading maker of medical devices.

Our Mission has not changed since Earl Bakken wrote it in 1960: To contribute to human welfare by application of biomedical engineering in the research, design, manufacture, and sale of instruments or appliances that alleviate pain, restore health and extend life.

More than 9 million lives are enhanced every year by a Medtronic product or therapy; that’s one every three seconds.

Medtronic is headquartered in Minneapolis, MN and operates in more than 140 countries. The company employs 46,000 people, including 5,800 scientists and engineers, pursuing research and innovation that has led to more than 28,000 patents.

Most Recent Press ReleasesRead More
DateTitle
07/28/14Medtronic Receives FDA Approval for PRESTIGE® LP Cervical Disc System
The PRESTIGE® LP Cervical Disc is Medtronic's Third Clinically-Proven Artificial Cervical Disc to Receive FDA Approval MEMPHIS, TENN. - July 28, 2014 - Medtronic, Inc. (NYSE: MDT) announces that it has received approval from the U.S. Food and Drug Administration (FDA) to market the PRESTIGE® LP Cervical Disc System for the treatment of single-level cervical disc disease (radiculopathy and/or myelopathy). The PRESTIGE® LP Cervical Disc is the third clinically proven artificial cervical disc in... 
07/28/14Medtronic Completes Acquisition of Visualase, Inc.
MRI-Guided Laser Ablation Technology Adds to Surgical Technologies Product Portfolio and Broader Neuroscience Leadership Position MINNEAPOLIS - July 28, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that it has completed the acquisition of Visualase, Inc., a privately held company based in Houston, TX, that develops and markets an FDA-approved MRI-guided laser and image guided system for minimally invasive neurosurgeries, including surgical thermal ablation.  Medtronic will add Visualase'... 
07/02/14People with Type 2 Diabetes Achieve Superior Outcomes with Insulin Pumps vs. Multiple Daily Injections
Comparative Efficacy Results from the OpT2mise Trial Published in The Lancet Could Redefine Management of Insulin-Requiring Type 2 Diabetes MINNEAPOLIS - July 2, 2014 - As an example of its commitment to improving clinical outcomes for all people with diabetes, Medtronic, Inc. (NYSE:MDT) today announced the results of the OpT2mise trial, which showed that MiniMed insulin pumps safely achieve better glucose control for people with insulin-requiring type 2 diabetes than multiple daily injections... 
Medtronic in the News
DateTitle
05/03/14Med-Tech Industry is Booming in China – Minneapolis Star Tribune
02/18/14The 50 Smartest Companies for 2014 – MIT Technology Review
02/18/14Innovation is just what the doctor ordered – Shanghai Daily
Receive E-mail Alerts E-mail Alert Icon
Sign up to receive e-mail alerts whenever Medtronic posts new information to the site. Just enter your e-mail address and click Submit.
 


Section Navigation

Spotlight

Medtronic to acquire Covidien. Learn More.

Media contact:
Fernando Vivanco
fernando.vivanco
@medtronic.com

763-505-3780

Contact Us

Medtronic
Medtronic, Inc.
main number(763) 514-4000
Medtronic
Public Relations
710 Medtronic Pkwy NE LC-110
Minneapolis, MN  55432

Media Contacts

Latest Tweets

Medtronic News
@Medtronic

Latest Tweets

Omar Ishrak
@MedtronicCEO